Literature DB >> 7724705

Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose.

M F Egan1, T M Hyde, J E Kleinman, R J Wyatt.   

Abstract

Rats treated chronically with neuroleptics develop vacuous chewing movements (VCMs), similar in some respects to tardive dyskinesia (TD) in man. The VCM syndrome was used as a model of TD to examine the ability of increased neuroleptic doses to produce long-term suppression of dyskinetic movements. The incidence and persistence of the VCM syndrome in individual rats were also assessed to look for affected and unaffected subgroups. Rats were initially treated for 15 weeks and haloperidol decanoate. For the next 21 weeks, half the group received a 50-150% increase in dose while the other half continued to receive the same dose. Animals were also followed during a 28-week withdrawal period. Total VCM ratings showed a skewed distribution, with some rats exhibiting few movements while others developed marked and persistent movements. Increasing doses did not suppress VCMs, nor did they exacerbate movements during the withdrawal period. To the extent that the VCM syndrome models TD, the absence of long-term suppression of the VCM syndrome suggests that, at this dosage range, increasing depot neuroleptic doses may not be a useful long-term strategy for TD suppression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7724705     DOI: 10.1007/bf02245101

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

1.  Long term treatment of tardive dyskinesia.

Authors:  A Jus; K Jus; P Fontaine
Journal:  J Clin Psychiatry       Date:  1979-02       Impact factor: 4.384

Review 2.  Pharmacological treatments of tardive dyskinesia in the 1980s.

Authors:  D V Jeste; J B Lohr; K Clark; R J Wyatt
Journal:  J Clin Psychopharmacol       Date:  1988-08       Impact factor: 3.153

3.  The course of tardive dyskinesia in patients on long-term neuroleptics.

Authors:  J A Bergen; E A Eyland; J A Campbell; P Jenkings; K Kellehear; A Richards; P J Beumont
Journal:  Br J Psychiatry       Date:  1989-04       Impact factor: 9.319

4.  Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate.

Authors:  H Kazamatsuri; C Chien; J O Cole
Journal:  Arch Gen Psychiatry       Date:  1972-07

5.  Management of tardive dyskinesia with thiopropazate.

Authors:  J P Curran
Journal:  Am J Psychiatry       Date:  1973-08       Impact factor: 18.112

6.  Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors.

Authors:  R E See; M Aravagiri; G D Ellison
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

7.  Clinical observations of the treatment of tardive dyskinesia with haloperidol.

Authors:  E Frangos; H Christodoulides
Journal:  Acta Psychiatr Belg       Date:  1975-01

8.  Effects of intravenous metoclopramide in 81 patients with tardive dyskinesia.

Authors:  D R Doongaji; D V Jeste; N M Jape; A S Sheth; J S Apte; V N Vahia; A B Desai; M D Parikh; L G Rathi; M H Ghandi; R M Parikh; S Thatte; J Bharadwaj
Journal:  J Clin Psychopharmacol       Date:  1982-12       Impact factor: 3.153

9.  Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats.

Authors:  N M Rupniak; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Pharmacologic characterization of tardive dyskinesia.

Authors:  J Lieberman; S Pollack; M Lesser; J Kane
Journal:  J Clin Psychopharmacol       Date:  1988-08       Impact factor: 3.153

View more
  5 in total

1.  Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy.

Authors:  William A Wolf; Gerald J Bieganski; Veronica Guillen; Laurence Mignon
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

2.  Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.

Authors:  T M Hyde; M F Egan; L L Wing; R J Wyatt; D R Weinberger; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

3.  Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats.

Authors:  Santhrani Thaakur; G Himabindhu
Journal:  J Neural Transm (Vienna)       Date:  2009-05-15       Impact factor: 3.575

4.  Effect of spirulina maxima on the haloperidol induced tardive dyskinesia and oxidative stress in rats.

Authors:  S R Thaakur; B Jyothi
Journal:  J Neural Transm (Vienna)       Date:  2007-05-26       Impact factor: 3.575

5.  Effect of 5-HT2A receptor antagonism on levels of D2/3 receptor occupancy and adverse behavioral side-effects induced by haloperidol: a SPECT imaging study in the rat.

Authors:  Stergios Tsartsalis; Benjamin B Tournier; Yesica Gloria; Philippe Millet; Nathalie Ginovart
Journal:  Transl Psychiatry       Date:  2021-01-14       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.